Can our paper-based clinical-trial model make the jump to the virtual world?

Deloitte June 21, 2019
Dawn Anderson, Managing director

I entered the pharmaceutical sector 32 years ago as a clinical research associate. In all that time, there has been surprisingly little change to the way biopharmaceutical companies and contract research organizations conduct clinical trials. While digital technology is widely available to the general population, it generally has not made its way into clinical trials. Most trials continue to use paper-based processes, which can make the process slow and inefficient.

Drug manufacturers might spend $2.6 billion to bring a new drug to market, according to a recent estimate from the Tufts Center for the Study of Drug Development. Every day that a new drug isn’t on the market could translate to $1 million dollars or more in lost revenue.¹

During...

Today's Sponsors

Today's Sponsor